Overview

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to investigate the safety, tolerability, and pharmacokinetics of TMC647055 in combination with ritonavir (Part 1); potential pharmacokinetic drug-drug interactions between TMC435 and the combination of TMC647055 with ritonavir; and to evaluate the short-term safety and tolerability when TMC435, TMC647055 and Ritonavir are co-administered (Part 2) in healthy Japanese participants.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen R&D Ireland

Treatments:

Cytochrome P-450 CYP3A Inhibitors
Ritonavir
Simeprevir